[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100476036":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":58,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"AdventHealth Translational Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Saline subcutaneous injection, volume matched to dulaglutide, i.e. 0.5 mL weekly for 14 weeks",[13],"Drug: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Dulaglutide","ACTIVE_COMPARATOR","Dulaglutide (0.75 mg\u002F0.5 mL weekly for 2 weeks, then 1.5 mg\u002F0.5 mL weekly for 12 weeks) subcutaneous injection",[19],"Drug: Dulaglutide",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","GLP1-RA",[15],null,{"type":22,"name":9,"description":27,"armGroupLabels":28,"otherNames":25},"Saline placebo",[9],[30],{"name":31,"affiliation":32,"role":33},"Kaitlin Love, MD","Site Principal Investigator","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Recruitment Department, MD","CONTACT","407-303-7100","CFD.TRI.Recruitment@AdventHealth.com",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Orlando","Florida","32804","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-81.37924,28.53834,{"lat":52,"lon":51},[55,57],{"name":56,"role":37,"phone":25,"phoneExt":25,"email":39},"Recruitment Department",{"name":31,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":33,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Kaitlin Love","Principal Investigator","100476036","phase-2-therapeutic-strategies-for-microvascular-dysfunction-in-type-1-diabetes-100476036",false,"NCT05478707","Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes","MCD-1","Inclusion criteria:\n\n* History of type 1 diabetes, duration \\> 5 years\n* Age 18-40 years\n* HbA1c \\\u003C 8.5%\n* BMI 19-34.9 kg\u002Fm2\n* Using insulin for diabetes treatment only (multiple daily injections or insulin pump with or without sensor augmentation)\n* On stable regimen of non-diabetic medications for the last 6 months\n* All screening labs within normal limits or not clinically significant - English or Spanish speaking\n\nExclusion criteria:\n\n* Pregnancy or currently breastfeeding\n* Smoking history within 6 months\n* History of microvascular (microalbuminuria, retinopathy, neuropathy) or macrovascular diabetes complications (coronary artery disease, stroke, peripheral vascular disease) as well as clinically significant cardiac arrhythmias or conduction disorders\n* Taking vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha-blockers).\n* Known hypersensitivity to perflutren (contained in Definity© contrast)\n* Screening O2 saturation \\\u003C90%\n* Musculoskeletal condition preventing participation in exercise testing or exercise training\n* Acute or unstable disease other than T1D\n* Hypoglycemia unawareness\n* History of gastroparesis, severe gastroesophageal reflux, pancreatitis, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2\n* Anemia (hemoglobin \\\u003C12 g\u002FdL in women, hemoglobin \\\u003C13 g\u002FdL in men), eosinophilia (absolute eosinophil count \\>500 cells\u002Fmicroliter) leukopenia (total white blood cells \\\u003C4,000 cells\u002Fmicroliter)\n* Diabetic ketoacidosis (DKA) on presentation to screening visits or study admission days\n* Hospital admission for DKA within 1 year","ALL","18 Years","40 Years",{"count":72,"type":73},47,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.",[79,80],"Diabetes Mellitus, Type 1","Endothelial Dysfunction",[82,83,15,84,85],"microvessels","oxidative stress","Glucagon-like peptide-1","Exercise therapy","2026-08-10",{"date":88,"type":89},"2026-08-12","ACTUAL",{"date":91,"type":89},"2023-10-05",{"date":93,"type":73},"2028-07-30",{"name":5,"class":6},1]